• Explore /
  • Poster
  • / Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Abstract Poster

Authors

null

Jennifer J. Knox

Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada

Jennifer J. Knox , Mairead Geraldine McNamara , Lipika Goyal , David Cosgrove , Christoph Springfeld , Katrin Marie Sjoquist , Joon Oh Park , Helena Verdaguer , Chiara Braconi , Paul J. Ross , Do-Youn Oh , Aimery De Gramont , John Raymond Zalcberg , Daniel H. Palmer , Juan W. Valle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04163900

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4164)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4164

Abstract #

TPS4164

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jennifer J. Knox

Poster

2019 ASCO Annual Meeting

NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.

NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.

First Author: Jennifer J. Knox

First Author: Jia Fan

First Author: Makoto Ueno